Innovative Approaches for Slowing Disease Progression in Parkinson's Disease: Takeaways from the 14th Annual International Society for Central Nervous System Clinical Trials and Methodology Scientific Meeting.

Monica Javidnia, Mark Frasier, Ira Shoulson, Ibrahim Turkoz, Kumar Budur

Open access · greenAbstract readReview

In one paragraph

Review in Innovations in clinical neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

1.0field-weighted citation impact, top 20% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 14 citations in OpenAlex.

Genetically-informed prediction of short-term Parkinson's disease progression.NPJ Parkinson's disease · 2022
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 3 countries.

Monica JavidniaDrs. Javidnia and Shoulson are with the Center for Health + Technology and the Department of Neurology, University of Rochester Medical Center in Rochester, New York.

Mark FrasierDrs. Javidnia and Shoulson are with the Center for Health + Technology and the Department of Neurology, University of Rochester Medical Center in Rochester, New York.

Ira ShoulsonDrs. Javidnia and Shoulson are with the Center for Health + Technology and the Department of Neurology, University of Rochester Medical Center in Rochester, New York.

Ibrahim TurkozDrs. Javidnia and Shoulson are with the Center for Health + Technology and the Department of Neurology, University of Rochester Medical Center in Rochester, New York.

Kumar BudurDrs. Javidnia and Shoulson are with the Center for Health + Technology and the Department of Neurology, University of Rochester Medical Center in Rochester, New York.

Michael J. Fox Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The International Society for Central Nervous System Clinical Trials and Methodology (ISCTM) partnered with the Michael J. Fox Foundation for Parkinson's Research to hold a joint session on innovation in Parkinson's disease research at the ISCTM 14th Annual Scientific Meeting held February 20 to 22, 2018 in Washington, D.C. The session focused on (1) biomarkers and outcomes measures in Parkinson's disease clinical trials; 2) clinical trial designs, outcomes, and statistical approaches; and 3) the path forward. This paper aims to summarize key takeaways from the session presenters, panelists, and audience members.

Indexed as

disease modificationdisease progressionParkinson’s diseaseprodromalRBD

Identifiers

PMID32547841

PMCPMC7239563

OpenAlexW3035717461

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.